BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 11, 2025
Home » Authors » Amanda Lanier

Articles by Amanda Lanier

Gray and green glass dollar symbols with arrow pointing up

Med-tech sector starts strong, with $6.28B in 2025 financings

March 10, 2025
By Amanda Lanier
Med-tech companies raised $3.52 billion in 65 deals in February 2025, up from $2.76 billion across 56 transactions in January.
Read More
Neurology illustration
Index insights

Intra-Cellular deal, Axsome settlement drive neurological index recovery

March 7, 2025
By Amanda Lanier
The BioWorld Neurological Diseases Index closed 2024 down 20.27%, extending its decline from -13.4% at the end of November. After falling to -12.2% in April, the index briefly rebounded, narrowing losses to under 4% by June, before experiencing a sharp downturn in the second half of the year.
Read More
Grey dollar sign on grey background
Biopharma financings February 2025

February financings slowing, but year outpaces 2022-2023

March 7, 2025
By Amanda Lanier
Biopharma companies raised $2.98 billion through 59 transactions in February 2025, down from $5.91 billion across 93 deals in January. The year is off to a slower start compared to 2023, with the $9.14 billion raised in the first two months, marking a 73% drop from $33.29 billion during the same period last year. However, this year's total is higher than the $7.66 billion raised in the first two months of 2023 and the $7.48 billion in 2022.
Read More
Clinical trial virtual display
Biopharma clinical updates January 2025

Phase III cancer successes in January include Itovebi, Libtayo, Rybrevant

Feb. 28, 2025
By Amanda Lanier
In January 2025, BioWorld tracked 171 phase I-III clinical trial updates, down from 212 in December. The month delivered 12 successful phase III outcomes, six of those in cancer, while two trials ended in failure.
Read More
Rebound arrows
Index insights

Biopharmaceutical index drops in 2024, but starts new year on a rebound

Feb. 27, 2025
By Amanda Lanier
The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it remained in positive territory through November, up 3.58%, the steady decline through the later months of the year pushed the index into the red by December’s close.
Read More
FDA Approved stamp with pills, bottle, blister pack
Biopharma regulatory actions and approvals January 2025

Astrazeneca, Vertex, Axsome secure US FDA approvals in January

Feb. 25, 2025
By Amanda Lanier
The U.S. FDA approved 12 drugs in January, falling below the 2024 monthly average of 19. Only three new molecular entities received approval, trailing the yearly average of just over four per month.
Read More
Handshake, businessmen holding dollar sign, lightbulb
Med-tech deals 4Q24

2024 saw more med-tech deals, but less value, as M&As outshine

Feb. 25, 2025
By Amanda Lanier
Despite the number of med-tech deals increasing to 1,902 in 2024, up 12% from 1,701 in 2023, the value of these deals has dramatically declined compared to previous years.
Read More
Gloved hand holding petri dish in lab
Index insights

Infectious disease index recovers from -25% low, ends 2024 down 6.28%

Feb. 24, 2025
By Amanda Lanier
The BioWorld Infectious Disease Index (BIDI) faced challenges throughout the year but narrowed its losses, ending down 6.28% after hitting a low of -25.12% in late April. By October, the index was down 12.07% and had declined 8.86% for the year as of Nov. 22. However, in January, the BIDI rebounded slightly, gaining 1.85%.
Read More
FDA Approved stamp with pills, bottle, blister pack
Biopharma regulatory actions and approvals January 2025

Astrazeneca, Vertex, Axsome secure US FDA approvals in January

Feb. 21, 2025
By Amanda Lanier
The U.S. FDA approved 12 drugs in January, falling below the 2024 monthly average of 19. Only three new molecular entities received approval, trailing the yearly average of just over four per month.
Read More
Drug R&D concept image.
Index insights

Drug developers struggle in 2024; Fibrogen, Acadia, Atai post gains

Feb. 19, 2025
By Amanda Lanier
The BioWorld Drug Developers Index extended its decline through year-end, closing 2024 down 15.25%. After dropping 11.3% by October, the index briefly rebounded, narrowing losses to 5.36% in November, before slipping again.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 31 32 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing